Medtronic plc achieved a robust revenue increase of 5.5% organically in the second quarter of fiscal 2026, reaching $9 billion, yet its stock declined by 1.99%. Despite this setback, the company continues to uphold its reputation for financial stability, having increased dividends for 48 consecutive years and maintaining a current yield of 2.9%. Medtronic is also progressing in its development of a robot-assisted surgical system and plans to expand into hernia repair and gynecology procedures in the U.S., signaling a commitment to innovation.
“Medtronic · declined · percentage · -1.99%”
“Medtronic plc · is a diversified global leader in medical technology · true · true”
“Medtronic · has revenue growth of · 5.5% organically in second-quarter fiscal 2026 · 5.5%”
“Medtronic · lost · percentage · -1.99%”
“Medtronic · is making · headway · own robot-assisted surgical system”
“Medtronic · had · strong Q2 FY2026 performance · $9 billion in revenue”
“Medtronic · has increased · its dividend · for 48 consecutive years”
“Medtronic PLC · has not lowered · dividend payouts · since 1978”
“Medtronic · lost · percentage · 1.99%”
“Medtronic · offers · yield · 2.9%”
“Medtronic · has · payout ratio · around 75%”
“Medtronic · has increased · dividend · for 48 consecutive years”